Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
End-stage renal disease (ESRD) is one of the leading causes of morbidity and mortality worldwide. Kidney Transplant (KT) remains to be the gold standard for all renal replacement therapies for ESRD. The transplant process includes induction therapy with an immunosuppressant. One of the most widely used induction agents is rabbit antithymocyte globulin (rATG). Induction therapy is done to prevent acute rejection, which in effect prolongs allograft and patient survival. The study aimed to determine the mean cumulative dose of rATG induction therapy among Filipino kidney transplant recipients (KTRs).
A retrospective cohort was conducted among 73 adult Filipino KTRs who underwent living donor kidney transplant at a tertiary medical center from 2016–2020. Patients were categorized into low- and high-dose rATG groups based on the mean cumulative dose (2.81 mg/kg). Outcomes assessed included renal function, delayed graft function, acute rejection- clinically and biopsy proven (BPAR), infection, malignancy, death censored graft failure (DCGF), and death with functioning graft (DWFG). Statistical analysis included Kaplan-Meier survival curves, Cox regression, and odds ratio estimation.
There were no statistically significant differences between the low (≤2.80 mg/kg) and high-dose (>2.80 mg/kg) groups in terms of acute rejection, DGF, DCGF, infection, or malignancy. However, a receiver operating characteristic (ROC) curve derived threshold dose of >4.34 mg/kg to be significantly associated with reduced patient survival (HR 27.6, p = 0.0075).
The mean cumulative dose of rATG in this cohort was 2.81 mg/kg, which is lower than the standard and high dose groups in similar East and South Asian Studies. In recent literature, high dose rATG was found to be greater than 4.5 mg/kg. The ROC-derived threshold dose of >4.34 mg/kg (HR 27.6, p = 0.0075) can be used as an upper dosing limit for safe induction therapy among Filipino KTRs. A larger, multi-center study in the Philippines, specifically in Kidney Transplant Centers, can be done to compare and validate results of this study.
